Recent Updates
Recently added Catalysts
CSBR Positive Sentiment

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Key Takeaway: Champions Oncology will present new data at the AACR 2026 Annual Meeting, showcasing eight studies that focus on oncology drug development. The research covers various cancer types and emphasizes the importance of understanding therapeutic responses and resistance. The company aims to help biopharma partners make informed decisions earlier in the development process. CEO Rob Brainin highlights the significance of combining patient-derived models with molecular data.
Price reaction · baseline $5.75 (2026-04-09 close) · hit pre-market · clean, no other CSBR news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of new data across eight studies at AACR 2026.
  • Focus on reducing translational risk in oncology drug development.
  • Use of patient-derived models to improve prediction of therapeutic responses.
  • Opportunity for collaboration and discussion with Champions Oncology scientists.

Full Press Release Details

Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions

HACKENSACK, NJ /ACCESS Newswire/ April 9, 2026 /Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California.
The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies. Together, the data underscore Champions Oncology's focus on helping biopharma partners better understand therapeutic response and resistance, identify actionable biomarkers, and make more informed development decisions earlier in the pipeline.
Using clinically relevant, patient-derived models together with integrated molecular, functional, and phenotypic data, the studies demonstrate how translationally relevant preclinical approaches can improve prediction, reduce development risk, and strengthen the connection between tumor biology and clinical strategy.
"At AACR 2026, we are presenting data that directly address one of the biggest challenges in oncology R&D, making better decisions earlier," said Rob Brainin, Chief Executive Officer of Champions Oncology. "By combining clinically relevant models with deep molecular and functional data, we can help our partners understand response, anticipate resistance, and move forward with greater confidence."
Champions Oncology scientists will be available throughout AACR 2026 to discuss study design, analytical approaches, and collaboration opportunities.
For more information on Champions Oncology's presence at AACR 2026, including poster details and meeting opportunities, visit:https://www.championsoncology.com/meet-us-at-aacr-2026

SOURCE:Champions Oncology, Inc.

Frequently Asked Questions

What will Champions Oncology present at AACR 2026?

Champions Oncology will present new data across eight studies related to oncology drug development.

Where is the AACR 2026 Annual Meeting held?

The AACR 2026 Annual Meeting will take place in San Diego, California.

What areas of oncology are covered in the presentations?

The presentations cover KRAS-mutant tumors, ovarian cancer, glioblastoma, and more.

How does Champions Oncology help biopharma partners?

They help partners understand therapeutic responses and identify actionable biomarkers.

Last updated: Apr 10, 2026